TXG (10x) Bozor qiymatining balans qiymatiga nisbati
10x Genomics, Inc. (TXG) mustahkam patent himoyasi va uskunalar almashtirishning yuqori xarajatlari tufayli genom tahlili sektorida yetakchiligini saqlab qolmoqda. Biznes to'qimalarni hujayra darajasida o'rganish uchun optika va mikrofluidikaning sinteziga tayanadi. Ushbu tarixiy narxlar grafigi aktivning dinamikasini namoyish etadi, bunda ko'rsatkich 12.20 darajasida turibdi. Biroq, mijozlar bazasi kengayishining sekinlashishi va marketing xarajatlarining ortishi kompaniyaning operatsion samaradorligini vaqtincha cheklashi mumkin.
%20Kapitallashuvning%20balans%20qiymatiga%20nisbati&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_TXG_-_10x-Genomics-Inc._-_Capitalization-to-Book-Value-Ratio "TXG 10x Genomics Corp Bozor kapitallashuvining balans qiymatiga nisbati (04.07.2022 - 28.10.2026) | 👁️GURU.Markets👁️")
10x Genomics Inc (TXG) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi bo'yicha ma'lumotlar:
- balans kapitallashuvi bo'yicha ma'lumotlar:
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati 10x Genomics, Inc.|TXG - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Qisqa muddatli qarzning o'z kapitaliga nisbati 10x Genomics Corp|TXG - Jamlangan qarz majburiyatlari|Balans kapitallashuviga qarzlar 10x Genomics Corp|TXG - Uzoq muddatli qarzdorlik|Kompaniyaning qisqa muddatli qarzlari 10x Genomics
Kompaniyaning dastlabki tahlili:10x Genomics, Inc. TXG
Portfel menejerlari 10x Genomics, Inc. (TXG) kompaniyasining operatsion modelini narxning buxgalteriya qiymatiga nisbati (P/B) orqali baholaydilar, bu ko'rsatkich sof aktivlardan yuqori bo'lgan investorlar premiumini va baholashning makrotsikllarga sezgirligini o'lchaydi. Kompaniyaga tegishli P/B nisbati tebranishlarining tahlili bozor kutuvlari nozik uskunalar uchun murakkab logistika xarajatlari bilan qanday bog'liqligini ko'rsatadi va likvidlik bosqichlaridagi o'zgarishlar davrida kapitalizatsiyaning barqarorligini belgilaydi.
Raqobatchilar tahlili
Bozor kapitallashuvining balans qiymatiga nisbati Tempus Labs|QGEN (qiagen.com) - Kapitallashuvning balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Ionis (IONS)|Kapitallashuvning balans qiymatiga nisbati Repligen Corp|Bozor kapitallashuvining balans qiymatiga nisbati RNA|Bozor kapitallashuvining balans qiymatiga nisbati CRISPR (CRSP)|Bozor kapitallashuvining balans qiymatiga nisbati GeneDx Holdings Corp. (WGS)|RARE - Bozor kapitallashuvining balans qiymatiga multiplikatori|Beam Therapeutics (BEAM) - Kapitallashuvning sof aktivlarga nisbati|Sarepta Therapeutics (SRPT) - Kapitallashuvning balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Twist Bio TWST|Intellia Corp (NTLA) - Balans qiymatiga nisbatan bozor qiymati|Stoke Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati biolifesolutions.com|Wave Life Sciences Ltd. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti MAZE (Maze Therapeutics, Inc.)|SION - Bozor qiymatining balans qiymatiga nisbati|Prime Medicine Bio - Kapitallashuvning balans qiymatiga nisbati|TSHA (Taysha Gene Therapies) - Bozor qiymatining balans qiymatiga nisbati|QURE: Bozor qiymatining balans qiymatiga koeffitsiyenti|MGTX (MeiraGTx) - Bozor qiymatining balans qiymatiga nisbati|REGENXBIO Inc (RGNX) - Kapitallashuvning sof aktivlarga nisbati|SLDB: Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Ocugen Pharma|Bozor kapitallashuvining balans qiymatiga nisbati PACB (Pacific Biosciences)|Kapitallashuvning sof aktivlarga nisbati BNTC (benitec.com)|Bozor qiymatining balans qiymatiga nisbati DSGN|RCKT - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati 4D Molecular Therapeutics Inc (FDMT)|LXEO - Balans qiymatiga nisbatan bozor qiymati|korrobio.com - Bozor kapitallashuvining balans qiymatiga nisbati|EDIT (editasmedicine.com) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Silence Therapeutics plc (SLN)|Kapitallashuvning balans qiymatiga nisbati ProQR Therapeutics NV|Bozor kapitallashuvining balans qiymatiga nisbati CDXS (Codexis, Inc.)|Kapitallashuvning sof aktivlarga nisbati Sangamo BioSciences SGMO|Kapitallashuvning sof aktivlarga nisbati NAUT|MGX - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati Precision BioSciences DTIL|Generation Bio Co. (GBIO) - Bozor kapitallashuvining balans qiymatiga multiplikatori|Kapitallashuvning sof aktivlarga nisbati Boundless Bio, Inc|Exicure (XCUR) - Kapitallashuvning balans qiymatiga nisbati|Imunon Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati RXi Pharmaceuticals|Bozor kapitallashuvining balans qiymatiga nisbati Mustang Bio, Inc. MBIO|Kapitallashuvning balans qiymatiga nisbati RNAZ (transcodetherapeutics.com)|BNGO - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati Applied DNA Corp APDN|bluebird bio, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|IPA - Bozor kapitallashuvining balans qiymatiga nisbati|OMGA - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga multiplikatori Singular Genomics Systems, Inc.|Kapitallashuvning sof aktivlarga nisbati Regulus Therapeutics Inc (RGLS)|Kapitallashuvning balans qiymatiga nisbati Syros Pharmaceuticals, Inc (SYRS)|Telesis Bio, Inc. (TBIO) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati traconpharma.com (TCON)|UBX (Unity Biotechnology, Inc.) - Bozor kapitallashuvining balans qiymatiga nisbati